Objective To investigate the characteristic of psychological health status and blood glucose in elderly patients with newly diagnosed type 2 diabetes for one year. Methods 48 patients in elderly with newly diagnosed type 2 diabetes were followed up on their blood glucose level and psychological status for one year. Results At newly diagnosed phase, fasting plasma glucose, 2 h postprandial plasma glucose and HbA1C were (9.48?2.67) mmol/L, (13.49?4.79) mmol/L and (8.89 ?2.74)%, but after 3months, those descended to (7.35?2.47) mmol/L, (10.01?3.14) mmol/L and (6.75?2.14)%, respectively. Compared with newly diagnosed phase, psychological happiness and living satisfaction improved; while the negative emotion, including depression, loneliness, hypochondriasis and anxiety, decreased consistent with the drop of blood glucose level after 3 months. Following 6 and 12 months, blood glucose and psychological heath status were stabilized on the whole. Conclusion Psychological status deteriorated seriously at newly diagnosed phase than in 3, 6 and 12 months, when is important phase for psychological intervention. Moreover, optimal glycemic control can promote psychological heath.

Migraine is a common neurological disease,and its pathogenesis is complex.So far,it has not been fully elucidated,nor has it obtained clinically accepted serum biomarkers.Accumulating evidence shows that microRNAs(miRNA),as a class of non-coding regulatory RNAs,not only participate in the pathophysiological mechanism of migraine but also are expected to be a potential biomarker of migraine and play an important role in the pathogenesis of migraine.This article reviews the research on migraine and miRNA,and provides new research ideas for further elucidating the pathogenesis of headache,marker screening,treatment response prediction,and future development of new prevention and treatment drugs.

Objective:To study the genetic profile of neonatal hyperbilirubinemia with unknown etiology in Guangdong Province and the clinical significance of jaundice-related genetic screening.Methods:From July to September, 2021, neonates with hyperbilirubinemia of unknown etiology born in different hospitals in Guangdong Province were studied. 24 neonatal jaundice-related exons were sequenced using targeted capture and high-throughput sequencing technology. The pathogenic variants were analyzed.Results:A total of 331 cases, 139 (42.0%) cases showed positive screening results with five diseases, including 65 (19.6%) cases of Gilbert syndrome, 48 (14.5%) cases of glucose-6-phosphate dehydrogenase (G6PD) deficiency,18 (5.4%) cases of sodium taurocholate cotransporting polypeptide deficiency, 4 (1.2%) cases of Citrin deficiency and 4 (1.2%) cases of Dubin-Johnson syndrome. 149 (45.0%) cases carried one or more genetic variants and 43 (13.0%) cases showed no clinically significant variants. The 8 high-frequency mutation loci (carrier rate >1%) are UGT1A1 gene c.211G>A and c.1091C>T, G6PD gene c.1466G>T and c.1478G>A, SLC10A1 gene c.800C>T, SLC25A13 gene c.852_855del TATG, HBB gene c.126_129delCTTT and c.316-197C>T.Conclusions:Genetic factors are important for neonatal hyperbilirubinemia with unknown etiology in Guangdong. The common pathogenic genes are UGT1A1, G6PD, SLC10A1, and SLC25A13 and the population carries high-frequency mutation loci. Therefore, genetic screening in neonates with hyperbilirubinemia of unknown etiology has important clinical significance.

Migraine is a common type of primary headache worldwide,and its high morbidity and disability rates have brought heavy burden to individuals and society,thereby requiring preventive and acute treatment.Previous thera-peutic strategies for migraine include traditional analgesics and triptans,which are mainly used to relieve pain and reduce accompanying symptoms,but long-term administration of such drugs may lead to medication overuse headache.In recent years,new drugs targeting calcitonin gene-related peptide(CGRP)and its receptors have shown a promising future in the preventive treatment of migraine and the treatment of migraine in the acute stage,such as monoclonal antibodies and small-molecular receptor antagonists,and in addition,they also can be used in patients who have no response to various pharma-cotherapies.This article reviews the recent advances in CGRP drugs in the treatment of migraine.